Latexin Activators
Latexin Activators constitute a diverse assortment of chemical compounds known for their potential to stimulate the activation of the protein latexin. This protein, encoded by the LXN gene in humans, is recognized as an endogenous carboxypeptidase inhibitor. Latexin plays a crucial role in the downregulation of metallocarboxypeptidases' activity, enzymes that essentially contribute to a range of cellular functions, including cell survival, growth, and differentiation.
The class of Latexin Activators includes a wide variety of compounds, each with its unique mechanism to interact with and activate latexin. These substances can be as diverse as proteasome inhibitors like Bortezomib, mTOR inhibitors such as Rapamycin, or NF-kappaB inhibitors like BAY 11-7082. Some activators work by altering protein synthesis and degradation pathways that could involve metallocarboxypeptidases and latexin. Others may influence gene expression or protein folding processes, potentially leading to enhanced latexin activation. Yet others, like autophagy inhibitors, might stimulate latexin by inducing an upregulation of certain protein degradation pathways. Despite the diverse range of mechanisms, all these compounds share the characteristic of potentially modulating the activity of latexin.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that may stimulate the activation of latexin by inducing upregulation of other protein degradation pathways, potentially involving metallocarboxypeptidases and latexin. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
A histone deacetylase (HDAC) inhibitor that may encourage the activation of latexin by modulating gene expression, potentially influencing the expression of latexin. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
An Hsp90 inhibitor that may foster the activation of latexin by modifying protein folding and degradation processes, potentially involving metallocarboxypeptidases and latexin. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An anthrapyrazolone inhibitor of Jun N-terminal kinase (JNK), which may encourage the activation of latexin by modifying apoptosis and protein degradation pathways, potentially involving metallocarboxypeptidases and latexin. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A potent and irreversible inhibitor of PI3K, which may promote the activation of latexin by modifying various cellular processes, including protein degradation pathways, potentially involving metallocarboxypeptidases and latexin. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
An inhibitor of NF-kappaB activation which may stimulate the activation of latexin by altering inflammation and immune responses, potentially impacting protein degradation and the activity of latexin. | ||||||
Calpeptin | 117591-20-5 | sc-202516 sc-202516A | 10 mg 50 mg | $121.00 $456.00 | 28 | |
A potent, cell-permeable calpain inhibitor that may promote the activation of latexin by inducing an upregulation of other protein degradation pathways, potentially involving metallocarboxypeptidases and latexin. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
A cell-permeable, irreversible pan-caspase inhibitor that may encourage the activation of latexin by inducing an upregulation of other protein degradation pathways, potentially involving metallocarboxypeptidases and latexin. | ||||||
Bestatin | 58970-76-6 | sc-202975 | 10 mg | $131.00 | 19 | |
An inhibitor of aminopeptidases that may stimulate the activation of latexin by inducing an upregulation of other protein degradation pathways, potentially involving metallocarboxypeptidases and latexin. | ||||||